论文部分内容阅读
Endocrine resistance and development of metastasis are some of the most important challenges in breast cancer treatment today.By quantitative mass spectrometry-based proteomic and transcriptomic analysis we are addressing these issues using breast cancer cell lines and large sets of clinical specimens from patients with well-defined medical histories and follow-up.A large panel of cell surface proteins that exhibit altered expression on metastasizing vs.non-metastasizing breast cancer cells has been identified and the clinical relevance of these cell surface markers is evaluated using large panels of clinical specimens.Further, we have identified a gene expression profile that, using microarray and quantitative real-time Reverse Transcriptase PCR (qRT-PCR) based TaqMan~ Low Density Array (LDA), can aid in predicting which estrogen receptor positive (ER+) breast cancer patients that will benefit from endocrine treatment.The profile is in the process of being validated and will aid clinicians in determining whether chemotherapy or other therapies should be added to standard treatment.The results of these studies will be discussed.